ω-Conotoxin GVIA Mimetics that Bind and Inhibit Neuronal Cav2.2 Ion Channels

C. Elisabet Tranberg, Aijun Yang, Irina Vetter, Jeffrey R. McArthur, Jonathan B. Baell, Richard J. Lewis, Kellie L. Tuck, Peter J. DugganMarine 2012 · DOI

TL;DR

Researchers have developed novel small-molecule mimics of ω-conotoxin GVIA, a potent blocker of neuronal calcium channels implicated in neuropathic pain. These new compounds, featuring a diphenylmethylpiperazine moiety, not only bind to the target channel but also effectively inhibit its function in cellular and electrophysiological assays, representing a significant step towards developing new pain therapeutics.

What Problem Does This Paper Address?

Neuropathic pain is a debilitating condition affecting a significant portion of the population, often inadequable to existing treatments. Neuronal voltage-gated N-type calcium channels (Ca<sub>v</sub>2.2) are a key target for pain management, with the natural toxin ω-conotoxin GVIA being a highly potent, albeit therapeutically impractical, blocker. The challenge lies in developing small-molecule drugs that can mimic the potent blocking activity of these natural peptides but possess better drug-like properties, such as oral bioavailability and reduced side effects. Previous attempts to create such mimics have shown promise, but a direct link between binding affinity and functional blockade in a dose-dependent manner for ω-conotoxin GVIA mimics has been elusive.

Methods

The study employed a multi-pronged approach to synthesize and evaluate novel ω-conotoxin GVIA mimetics:

  • Chemical Synthesis: A library of anthranilamide-based compounds was synthesized, with a key modification being the incorporation of a diphenylmethylpiperazine moiety. This involved a multi-step synthesis starting from a nitro ester precursor, leading to diazide intermediates, and finally to the target diamine and diguanidino compounds.
  • Radioligand Displacement Assay: This standard technique was used to assess the binding affinity of the synthesized compounds to Ca<sub>v</sub>2.2 channels. Radiolabeled ω-conotoxin GVIA was used to compete with the test compounds for binding sites on rat brain homogenates.
  • Fluorescence-Based Calcium Response Assay: SH-SY5Y neuroblastoma cells, which express Ca<sub>v</sub>2.2 channels, were used to measure intracellular calcium responses. These responses, elicited by depolarization, were monitored using a calcium-sensitive fluorescent dye. The ability of the compounds to inhibit these responses was assessed.
  • Whole-Cell Patch Clamp Electrophysiology: This gold-standard technique was employed to directly measure the functional activity of Ca<sub>v</sub>2.2 channels. HEK293 cells stably expressing human Ca<sub>v</sub>2.2 channels were used to record calcium currents, allowing for the determination of the compounds' inhibitory effects on channel function.

Datasets

Not discussed in the paper. The study relies on established biological assays and synthesized chemical compounds rather than pre-existing datasets.

Key Insights and Ideas

  • The Diphenylmethylpiperazine Moiety is Crucial: Compounds lacking the diphenylmethyl functionality showed no significant binding affinity in the radioligand assay, strongly suggesting this structural feature is essential for high-affinity binding to Ca<sub>v</sub>2.2 channels in this class of mimetics.
  • Diguanidino Compounds Show Superior Binding: Similar to previous studies, the diguanidino derivatives (8a and 8b) exhibited significantly stronger binding affinities compared to their diamino counterparts (7a and 7b).
  • Bridging the Gap Between Binding and Function: This study successfully demonstrated that compounds active in the radioligand displacement assay also exhibit functional inhibition of Ca<sub>v</sub>2.2 channels in both cellular and electrophysiological assays. This is a critical finding, as it validates the binding assay as a reliable predictor of functional activity for these mimetics.
  • Improved Inhibition in Functional Assays: The newly synthesized diphenylmethylpiperazine-substituted compounds showed improved inhibition of intracellular calcium responses in SH-SY5Y cells compared to previously reported phenoxyaniline-bearing compounds.
  • Potency Shift in Functional Assays: As observed with native ω-conotoxins, the potency of these mimetics was reduced in functional assays compared to binding assays. This is attributed to factors like the presence of auxiliary subunits and physiological Ca<sup>2+</sup> levels, which can influence channel activity.

Key Results

  • Compounds 7a, 7b, 8a, and 8b showed moderate to good binding affinity in the radioligand displacement assay.
  • Diguanidino compounds (8a and 8b) demonstrated the strongest binding, comparable to previously reported anthranilamides.
  • In the fluorescence-based assay, compounds 7a, 8a, and 8b partially inhibited KCl-elicited calcium responses in SH-SY5Y cells, with 7b being less efficacious. Dose-dependent inhibition was observed, allowing for IC<sub>50</sub> estimations.
  • Patch-clamp experiments on HEK293 cells confirmed that compounds 7a, 7b, and 8a (at 30 and 100 µM) and 8b (at 30 µM) showed modest inhibition of Ca<sub>v</sub>2.2 currents.
  • Compound 8b emerged as the most effective Ca<sub>v</sub>2.2 channel blocker among those examined, showing consistent results across different assays. Its IC<sub>50</sub> values were comparable between the FLIPR-Ca<sup>2+</sup> assay and patch-clamp electrophysiology.

Limitations and Future Work

  • Potency Shift: The observed decrease in potency in functional assays compared to binding assays is a limitation. The authors suggest that this could be due to the influence of co-expressed auxiliary subunits and the experimental conditions (e.g., incubation time with extracellular divalent cations).
  • Drug-like Properties: While the diphenylmethylpiperazine moiety is considered less likely to cause toxic effects than the phenoxyaniline substituent, further optimization is needed to improve overall drug-like properties, such as oral bioavailability.
  • Future Directions: The study highlights compound 8b as a promising candidate for further optimization. Future work will focus on improving its potency and incorporating more drug-like characteristics to develop it into a potential therapeutic agent for neuropathic pain. The authors also suggest that the findings validate the use of ω-conotoxin GVIA as a starting point for designing Ca<sub>v</sub>2.2 channel blockers and the radioligand displacement assay as an initial screening tool.

Summary updated

Abstract

The neuronal voltage-gated N-type calcium channel (Ca(v)2.2) is a validated target for the treatment of neuropathic pain. A small library of anthranilamide-derived ω-Conotoxin GVIA mimetics bearing the diphenylmethylpiperazine moiety were prepared and tested using three experimental measures of calcium channel blockade. These consisted of a ¹²⁵I-ω-conotoxin GVIA displacement assay, a fluorescence-based calcium response assay with SH-SY5Y neuroblastoma cells, and a whole-cell patch clamp electrophysiology assay with HEK293 cells stably expressing human Ca(v)2.2 channels. A subset of compounds were active in all three assays. This is the first time that compounds designed to be mimics of ω-conotoxin GVIA and found to be active in the ¹²⁵I-ω-conotoxin GVIA displacement assay have also been shown to block functional ion channels in a dose-dependent manner.
BibTeX
@inproceedings{tranberg2012conotoxin,
  author = {C. Elisabet Tranberg and Aijun Yang and Irina Vetter and Jeffrey R. McArthur and Jonathan B. Baell and Richard J. Lewis and Kellie L. Tuck and Peter J. Duggan},
  title = {{ω-Conotoxin GVIA Mimetics that Bind and Inhibit Neuronal Cav2.2 Ion Channels}},
  booktitle = {Marine},
  year = {2012},
  doi = {10.3390/md10102349},
}
Figure